Secrets of lung cancer spread found in patients’ blood and biopsies

byCancer Research UK| News7 October 2019Early signs that a patient’s lung cancer may spread and become untreatable can be picked up in samples of their blood and tumour, according to a tri

Updated on: December 19,2023 35

Secrets of lung cancer spread found in patients’ blood and biopsies

byCancer Research UK| News7 October 2019Early signs that a patient’s lung cancer may spread and become untreatable can be picked up in samples of their blood and tumour, according to a tri

Updated on:December 19,2023 35

Testing cells for cancer drug resistance

byRuhr-Universitaet-BochumSamir El-Mashtoly (right) and Klaus Gerwert in the lab at Ruhr-Universität Bochum. Credit: Michael SchwettmannBiophysicists at Ruhr-Universität Bochum (RUB) have demons

Updated on: December 18,2023 12

Testing cells for cancer drug resistance

byRuhr-Universitaet-BochumSamir El-Mashtoly (right) and Klaus Gerwert in the lab at Ruhr-Universität Bochum. Credit: Michael SchwettmannBiophysicists at Ruhr-Universität Bochum (RUB) have demons

Updated on:December 18,2023 12

Immunotherapy may become new first line treatment in some metastatic colorectal cancers

byEuropean Society for Medical OncologyCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0Immunotherapy with nivolumab and low-dose ipilimumab could become a new fi

Updated on: December 18,2023 19

Immunotherapy may become new first line treatment in some metastatic colorectal cancers

byEuropean Society for Medical OncologyCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0Immunotherapy with nivolumab and low-dose ipilimumab could become a new fi

Updated on:December 18,2023 19

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on: October 11,2023 205

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on:October 11,2023 205

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22, 2022Caroline SeymourThe score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–sma

Updated on: October 17,2023 34

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22, 2022Caroline SeymourThe score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–sma

Updated on:October 17,2023 34

Immune cell discovery opens door to new powerful cancer therapies

byUniversity College LondonCredit: CC0 Public DomainScientists at UCL have identified how a subset of immune cells are activated to kill cancerous cells, a finding in mice which could hold the k

Updated on: December 20,2023 16

Immune cell discovery opens door to new powerful cancer therapies

byUniversity College LondonCredit: CC0 Public DomainScientists at UCL have identified how a subset of immune cells are activated to kill cancerous cells, a finding in mice which could hold the k

Updated on:December 20,2023 16

Proton therapy lowers risk of side effects in cancer compared to traditional radiation

byPerelman School of Medicine at the University of PennsylvaniaStudy finds protons led to two-thirds reduction in unplanned hospitalizations. Credit: Penn MedicineProton therapy leads to signifi

Updated on: December 20,2023 19

Proton therapy lowers risk of side effects in cancer compared to traditional radiation

byPerelman School of Medicine at the University of PennsylvaniaStudy finds protons led to two-thirds reduction in unplanned hospitalizations. Credit: Penn MedicineProton therapy leads to signifi

Updated on:December 20,2023 19

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest

Updated on: October 11,2023 261

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest

Updated on:October 11,2023 261

Targeting epiregulin in treatment-damaged tumor microenvironment restrains therapeutic resistance

by Liu Jia,Chinese Academy of SciencesGenotoxicity induces expression of EREG and other secreted factors of the SASP spectrum in human stromal cells.aTranscriptome-wide profiling of

Updated on: December 19,2023 10

Targeting epiregulin in treatment-damaged tumor microenvironment restrains therapeutic resistance

by Liu Jia,Chinese Academy of SciencesGenotoxicity induces expression of EREG and other secreted factors of the SASP spectrum in human stromal cells.aTranscriptome-wide profiling of

Updated on:December 19,2023 10

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on: December 21,2023 10

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on:December 21,2023 10

Universal genetic testing may improve risk stratification and treatment for rare and lethal cancer

Esophageal adenocarcinoma (EAC) is a highly lethal cancer, with a five-year survival rate of less than 20 percent. Although a precursor lesion to EAC, called Barrett's esophagus (BE), is present i

Updated on: November 19,2023 18

Universal genetic testing may improve risk stratification and treatment for rare and lethal cancer

Esophageal adenocarcinoma (EAC) is a highly lethal cancer, with a five-year survival rate of less than 20 percent. Although a precursor lesion to EAC, called Barrett's esophagus (BE), is present i

Updated on:November 19,2023 18

Patients prefer stool test to colonoscopy

byCedars-Sinai Medical CenterGraphical abstract. Credit:Clinical Gastroenterology and Hepatology(2022). DOI: 10.1016/j.cgh.2022.07.012Three-quarters of people prefer to do a fecal im

Updated on: December 19,2023 10

Patients prefer stool test to colonoscopy

byCedars-Sinai Medical CenterGraphical abstract. Credit:Clinical Gastroenterology and Hepatology(2022). DOI: 10.1016/j.cgh.2022.07.012Three-quarters of people prefer to do a fecal im

Updated on:December 19,2023 10